ALGS Aligos Therapeutics, Inc.
Price Chart
Executive Summary
Aligos Therapeutics reported financial results for Q4 and full year 2025, showing improved net losses compared to the prior year due to reduced expenses and a $60.2 million gain from the change in fair value of common warrants. The company highlighted clinical progress in its HBV and obesity/MASH programs, including advancement of ALG-170675 into IND-enabling studies and preclinical data showing synergistic weight loss with ALG-055009. Cash totaled $77.8 million as of December 31, 2025, sufficient into Q3 2026.
Key Financial Metrics
Actionable Insight
The improved financials are largely driven by non-operational gains; traders should focus on upcoming clinical milestones in 2026 and 2027. The preclinical obesity data is promising but early-stage; monitor for partnership or out-licensing developments for ALG-055009.
Key Facts
- Net loss for FY 2025 was $24.2 million vs. $131.2 million in FY 2024, primarily due to a $60.2 million gain from warrant fair value changes.
- Cash, cash equivalents, and investments totaled $77.8 million as of December 31, 2025, up from $56.9 million a year prior.
- Pevifoscorvir sodium Phase 2 B-SUPREME study completed enrollment in HBeAg- cohort; interim analyses expected in 2026, topline data in 2027.
- ALG-170675 advanced into IND-enabling studies in partnership with Amoytop, with development costs in China funded by Amoytop.
- Preclinical data showed ALG-055009 combined with incretin agonists (semaglutide or tirzepatide) produced up to 40% body weight loss in mice, significantly higher than monotherapy.
Financial Impact
Net loss improved by $107 million YoY due to non-recurring warrant fair value gain; R&D and G&A expenses declined slightly. No revenue from collaborations in 2025.
Risk Factors
- Financial improvement is primarily due to non-recurring warrant valuation changes, not operational performance.
- No revenue from collaborations in 2025, raising concerns about near-term funding sustainability.
- Clinical programs remain in early stages with data readouts not expected until 2027.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-001340 |
| Document: f8k_030426.htm | 0001171843-26-001340 |
| Document: 0001171843-26-001340-index-headers.html | 0001171843-26-001340 |
| Document: 0001171843-26-001340-index.html | 0001171843-26-001340 |
| Document: 0001171843-26-001340.txt | 0001171843-26-001340 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
19d ago
|
Press Release
| $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | $5.28 (−5.71%) |
|
Apr 16, 2026
8w ago
|
Press Release
| $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | $5.28 (−31.07%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | $5.28 (−28.84%) |
|
Mar 5, 2026
14w ago
|
8-K
| $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $5.28 (−20.72%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $5.28 (−20.72%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | $5.28 (−24.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access